Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR.

BACKGROUND Cystic fibrosis is a life-limiting disease that is caused by defective or deficient cystic fibrosis transmembrane conductance regulator (CFTR) protein activity. Phe508del is the most common CFTR mutation. METHODS We conducted two phase 3, randomized, double-blind, placebo-controlled studies that were designed to assess the effects of lumacaftor (VX-809), a CFTR corrector, in combination with ivacaftor (VX-770), a CFTR potentiator, in patients 12 years of age or older who had cystic fibrosis and were homozygous for the Phe508del CFTR mutation. In both studies, patients were randomly assigned to receive either lumacaftor (600 mg once daily or 400 mg every 12 hours) in combination with ivacaftor (250 mg every 12 hours) or matched placebo for 24 weeks. The primary end point was the absolute change from baseline in the percentage of predicted forced expiratory volume in 1 second (FEV1) at week 24. RESULTS A total of 1108 patients underwent randomization and received study drug. The mean baseline FEV1 was 61% of the predicted value. In both studies, there were significant improvements in the primary end point in both lumacaftor-ivacaftor dose groups; the difference between active treatment and placebo with respect to the mean absolute improvement in the percentage of predicted FEV1 ranged from 2.6 to 4.0 percentage points (P<0.001), which corresponded to a mean relative treatment difference of 4.3 to 6.7% (P<0.001). Pooled analyses showed that the rate of pulmonary exacerbations was 30 to 39% lower in the lumacaftor-ivacaftor groups than in the placebo group; the rate of events leading to hospitalization or the use of intravenous antibiotics was lower in the lumacaftor-ivacaftor groups as well. The incidence of adverse events was generally similar in the lumacaftor-ivacaftor and placebo groups. The rate of discontinuation due to an adverse event was 4.2% among patients who received lumacaftor-ivacaftor versus 1.6% among those who received placebo. CONCLUSIONS These data show that lumacaftor in combination with ivacaftor provided a benefit for patients with cystic fibrosis homozygous for the Phe508del CFTR mutation. (Funded by Vertex Pharmaceuticals and others; TRAFFIC and TRANSPORT ClinicalTrials.gov numbers, NCT01807923 and NCT01807949.).

[1]  M. Rosenfeld,et al.  Lumacaftor/Ivacaftor in Patients Aged 6‐11 Years with Cystic Fibrosis and Homozygous for F508del‐CFTR , 2017, American journal of respiratory and critical care medicine.

[2]  A Cremonesi,et al.  Clinical endpoints in peripheral endovascular revascularization trials: a case for standardized definitions. , 2008, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[3]  T. Liou,et al.  Predictive 5-year survivorship model of cystic fibrosis. , 2001, American journal of epidemiology.

[4]  L. Saiman,et al.  Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. , 2003, JAMA.

[5]  G. A. Whitmore,et al.  A contemporary survival analysis of individuals with cystic fibrosis: a cohort study , 2014, European Respiratory Journal.

[6]  N. Dokholyan,et al.  Potentiator ivacaftor abrogates pharmacological correction of ΔF508 CFTR in cystic fibrosis , 2014, Science Translational Medicine.

[7]  S. McColley,et al.  A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial. , 2014, The Lancet. Respiratory medicine.

[8]  J. Riordan,et al.  Multiple proteolytic systems, including the proteasome, contribute to CFTR processing , 1995, Cell.

[9]  J. Bradley,et al.  Quality of life and healthcare utilisation in cystic fibrosis: a multicentre study , 2012, European Respiratory Journal.

[10]  P. Hiatt,et al.  Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation. , 2014, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[11]  Pascal Barbry,et al.  Altered chloride ion channel kinetics associated with the ΔF508 cystic fibrosis mutation , 1991, Nature.

[12]  S. Doucette,et al.  Exacerbation frequency and clinical outcomes in adult patients with cystic fibrosis , 2011, Thorax.

[13]  G. Lukács,et al.  Some gating potentiators, including VX-770, diminish ΔF508-CFTR functional expression , 2014, Science Translational Medicine.

[14]  F. Vermassen,et al.  A call for uniform reporting standards in studies assessing endovascular treatment for chronic ischaemia of lower limb arteries. , 2007, European heart journal.

[15]  Emily A. Knapp,et al.  Longevity of Patients With Cystic Fibrosis in 2000 to 2010 and Beyond: Survival Analysis of the Cystic Fibrosis Foundation Patient Registry , 2014, Annals of Internal Medicine.

[16]  J. Mainz,et al.  Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. , 2013, American journal of respiratory and critical care medicine.

[17]  C. Goss,et al.  Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study. , 2017, The Lancet. Respiratory medicine.

[18]  J L Hankinson,et al.  Spirometric reference values from a sample of the general U.S. population. , 1999, American journal of respiratory and critical care medicine.

[19]  F. van Goor,et al.  Effect of ivacaftor on CFTR forms with missense mutations associated with defects in protein processing or function. , 2014, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[20]  Umer Khan,et al.  Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis. , 2014, American journal of respiratory and critical care medicine.

[21]  P. Negulescu,et al.  Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809 , 2011, Proceedings of the National Academy of Sciences.

[22]  S Grinstein,et al.  The delta F508 mutation decreases the stability of cystic fibrosis transmembrane conductance regulator in the plasma membrane. Determination of functional half-lives on transfected cells. , 1993, The Journal of biological chemistry.

[23]  J. Clancy,et al.  Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation , 2011, Thorax.

[24]  M. Corey,et al.  Energy expenditure of patients with cystic fibrosis. , 1987, The Journal of pediatrics.

[25]  Ying Jiang,et al.  Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp-CFTR mutation: a phase 3, open-label extension study (PERSIST). , 2014, The Lancet. Respiratory medicine.

[26]  A. Quittner,et al.  Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. , 2009, Chest.

[27]  D. Waltz,et al.  143 Lumacaftor/ivacaftor combination therapy in CF patients homozygous for F508del-CFTR with severe lung dysfunction , 2015 .

[28]  James Rader,et al.  Rescue of DeltaF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules. , 2006, American journal of physiology. Lung cellular and molecular physiology.

[29]  B. Kerem,et al.  Consensus on the Use and Interpretation of Cystic Fibrosis Mutation Analysis in Clinical Practice , 2022 .

[30]  David Wypij,et al.  Pulmonary function between 6 and 18 years of age , 1993, Pediatric pulmonology.

[31]  P. Negulescu,et al.  Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770 , 2009, Proceedings of the National Academy of Sciences.

[32]  W. Morgan,et al.  Risk factors for rate of decline in FEV1 in adults with cystic fibrosis. , 2012, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[33]  G. Lukács,et al.  Conformational and Temperature-sensitive Stability Defects of the ΔF508 Cystic Fibrosis Transmembrane Conductance Regulator in Post-endoplasmic Reticulum Compartments* , 2001, The Journal of Biological Chemistry.

[34]  M. Amaral,et al.  Most F508del-CFTR Is Targeted to Degradation at an Early Folding Checkpoint and Independently of Calnexin , 2005, Molecular and Cellular Biology.

[35]  Milan Macek,et al.  Cystic fibrosis: A worldwide analysis of CFTR mutations—correlation with incidence data and application to screening , 2002, Human mutation.

[36]  J. Zieleński,et al.  The molecular genetic epidemiology of cystic fibrosis: Report of a joint meeting of WHO/ECFTN/ICF(M)A/ECFS , 2004 .

[37]  E. Elkin,et al.  Year-to-year changes in lung function in individuals with cystic fibrosis. , 2010, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[38]  S. Freedman,et al.  Cystic fibrosis , 2009, The Lancet.

[39]  M. Schluchter,et al.  Clinical use of Ibuprofen is associated with slower FEV1 decline in children with cystic fibrosis. , 2007, American journal of respiratory and critical care medicine.

[40]  Matthias Griese,et al.  A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. , 2011, The New England journal of medicine.

[41]  G. Sawicki,et al.  Sustained Benefit from ivacaftor demonstrated by combining clinical trial and cystic fibrosis patient registry data. , 2015, American journal of respiratory and critical care medicine.

[42]  Mark R Elkins,et al.  A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. , 2006, The New England journal of medicine.

[43]  Karen A Robinson,et al.  Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. , 2007, American journal of respiratory and critical care medicine.

[44]  F. van Goor,et al.  Ivacaftor potentiation of multiple CFTR channels with gating mutations. , 2012, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[45]  T. Liou,et al.  Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation. , 2012, Chest.